From molecular case studies: Genomics of exceptional responder to NOTCH inhibitor

6 octubre 2015

Normal T-cell development requires Notch signaling but hyperactivity can lead to cancer. Drugs that inhibit Notch, such as gamma-secretase inhibitors, are currently being tested in different cancer types but clinical remission has yet to be reported. In a new paper, researchers describe an acute lymphoblastic leukemia patient in which GSI treatment resulted in complete remission, suggesting that GSIs may hold therapeutic promise in ALL and other cancers.
http://www.sciencedaily.com/releases/2015/10/151006123752.htm

Volver